Bluejay Diagnostics, Inc. 8K

Bluejay Diagnostics reported significant progress in its SYMON-II pivotal trial with 624 of 750 patients enrolled, advancing clinical validation of its Symphony IL-6 sepsis test.

On April 7, 2026, Bluejay Diagnostics, Inc. announced via press release that it has successfully enrolled 624 patients in its ongoing SYMON-II pivotal clinical trial evaluating the Symphony IL-6 test for sepsis triage and monitoring in critical care settings, representing substantial progress toward the study’s 750-patient enrollment target, which the company expects to complete within the next two to three months and which is intended to support clinical validation of the Symphony platform and a future 510(k) submission to the FDA.

Filing Facts

CIK

1704287

Ticker

-

Form

8K

Source Type

sec

Accession

0001213900-26-040728

Alert Tier

6